Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton
Marina
M
Breast Unit, The Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom.
Smith
Ian E
IE
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control; D010053:Ovary / Q000187:drug effects; D017697:Premenopause; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone